Last reviewed · How we verify

Cyproviron — Competitive Intelligence Brief

Cyproviron (CYPROTERONE ACETATE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cyproterone. Area: Pain.

discontinued cyproterone Androgen receptor, Glucocorticoid receptor, Mu-type opioid receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

Cyproviron (CYPROTERONE ACETATE). Cyproterone acetate works by binding to the progesterone receptor, thereby blocking the effects of androgens and estrogens on the body.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cyproviron TARGET CYPROTERONE ACETATE discontinued cyproterone Androgen receptor, Glucocorticoid receptor, Mu-type opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cyproterone class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyproviron — Competitive Intelligence Brief. https://druglandscape.com/ci/cyproterone-acetate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: